Seegene partners with Springer Nature to develop 15 diagnostic reagents

2023. 9. 5. 10:57
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Image captured from Seegene homepage]
Seegene Inc., a South Korean manufacturer of in vitro diagnostic products, initiated a global project to develop diagnostic reagents with Springer Nature, the U.K. publisher of the scientific journal “Nature.” Named the “Open Innovation Program Powered by Seegene,” the project is the duo’s first collaboration following their strategic partnership agreement for technology sharing in June.

Seegene announced on Monday that it began recruiting applicants for its Open Innovation Program with Springer Nature. The program consists of 15 designated tasks to develop 15 new syndromic quantitative polymerase chain reaction (PCR) diagnostic reagents for specific conditions including urinary tract infections, dermatophytosis, sexually transmitted infections, and vaginitis. Seegene and Springer Nature will select clinical trial participants by the end of October and hopes to start reagent development in March 2024, when the selection process is due to be completed. Clinical research participants will be grouped into teams of at least two, including Ph.D. level personnel, working at universities or research institutions. The selected participants will also receive a maximum of $600,000 per project. A Seegene official said that “Although Seegene will lead the first program, participants will be in charge of the entire process from the initial development stages to clinical validation moving forward.”

Seegene inked a partnership agreement for technology sharing with Springer Nature in June. Under the agreement, Seegene will share its diagnostic and data analysis technology, known as the OneSystem™ Business, with leading companies in various countries and engage scientists from around the world to develop customized diagnostic products tailored to local needs. With this collaboration, Seegene will be able to leverage Springer Nature’s credibility to establish a global network of experts. Nature plans to showcase Seegene’s reagent development projects to the scientific community in the publication, enabling projects to be commercialized by combining the company’s technological prowess with global experts’ ideas and research outcomes.

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?